Erschienen in:
01.06.2007 | Letter
Conclusions regarding the efficacy of treatments for neuroleptic malignant syndrome should be tempered given poor quality data, regardless of the analysis conducted
verfasst von:
Darren M Roberts, Jason A Roberts
Erschienen in:
Critical Care
|
Ausgabe 3/2007
Einloggen, um Zugang zu erhalten
Excerpt
We read with interest the analysis by Reulbach and colleagues regarding the treatment of neuroleptic malignant syndrome (NMS) [
1]. In this analysis, the effect of various treatments on clinical outcomes from 271 single case reports was reviewed. It was concluded that dantrolene does not seem to be the evidence-based treatment of choice for NMS. …